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recall system in a tertiary-referral centre forAIM: To review the radiology-led ultrasound (US) surveillance programme for the detection
of hepatocellular carcinoma (HCC) in cirrhotic patients in a UK tertiary-referral centre.
MATERIALS AND METHODS: The radiology information system was searched for patients
who had undergone US for surveillance of cirrhosis from September 2009 to May 2013. Patient
demographics and cirrhosis aetiology were documented. Data including numbers of surveil-
lance scans, abnormal ﬁndings suspicious for HCC, subsequent radiological investigations,
numbers of HCC and survival for HCC patients were recorded. Service performance data, such
as rates of attendance and rebooking, were also recorded.
RESULTS: Eight hundred and four patients entered surveillance and 2,366 surveillance US
examinations were performed; 368 (46%) underwent follow-up (6-monthly US). Abnormalities
leading to further radiological investigations were found in 81 patients. Reasons for incomplete
surveillance included non-attendance and radiology failure to re-book appointments. HCC was
diagnosed in 22 patients. Fourteen had HCC diagnosed on a surveillance scan, eight had HCC
diagnosed on a scan performed for other reasons. Patients diagnosed with HCC on a surveil-
lance scan were more likely to be treated with curative intent and had longer survival.
CONCLUSION: Even with a radiology-led recall service for HCC surveillance, the proportion
of patients receiving scans 6-monthly was low, due in part to the lack of organisational support
that is available for other screening programmes. This study gives a realistic representation of
the implementation of surveillance in a UK hospital at the current time and of the rates of HCC
proceeding to treatment.
 2016 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.artment of Radiology, The Royal Liverpool Hospital, Prescot Street, Liverpool UK. Tel.: þ44 0151 706 2000.
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Hepatocellular carcinoma (HCC) incidence is rising in the
UK and globally, constituting part of a wider trend of
increased mortality from chronic liver disease.1,2 The ma-
jority of HCC cases occur in patients with cirrhosis. The rise
in cirrhosis has been attributed to an increased prevalence
of chronic hepatitis B (CHB) and chronic hepatitis C (CHC)
infections in addition to non-alcoholic fatty liver disease
(NAFLD) and alcoholic liver disease (ALD).3,4 Globally, HCC is
the third leading cause of cancer death, due to the impact of
CHB infection in Africa and Asia.5
The prognosis of HCC is related to the stage of disease at
presentation and is dependent on several variables
including: tumour size; the number of cancerous nodules;
extra-hepatic disease; portal vein invasion by tumour; and
underlying liver function. Patients with cancers that are
potentially amenable to curative treatment (trans-
plantation, resection, or ablation) have a 3-year survival rate
between 60e80%.6 In comparison, the prognosis for pa-
tients presenting with advanced HCC remains poor with 3
year survival rates as low as 10%.7,8
Small tumours are asymptomatic and the aim of sur-
veillance is to identify patients with early, curable tumours
using ultrasound (US) screening followed by cross-sectional
imaging (Figs 1e2). HCC surveillance, in selected high-risk
patient groups, is recommended by several international
liver associations (e.g., the American Association for the
Study of Liver Diseases [AASLD], the European Association
for the Study of the Liver [EASL], and the British Society
of Gastroenterology [BSG]).9e11 The most commonFigure 1 (a) US image of a cirrhotic patient shows a nodule in the right l
shows avid arterial enhancement. (c) Portal venous phase CT shows wash
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fetoprotein (AFP) measurement every 6 months in pa-
tients with compensated cirrhosis.
Robust evidence supporting the beneﬁt of surveillance is
lacking.12 This was acknowledged in a Royal College of
Radiology (RCR) position statement published in September
2014.13 In the UK, there is currently no speciﬁc funding for
surveillance, nor is there the organisational support that is
available in other screening programmes such as for breast
and colon cancer. Yet, both patients and clinicians have an
expectation that surveillance will be offered. The provision
of US surveillance for HCC in the UK is inconsistent and
poorly performed. This was conﬁrmed by a recent survey of
current practice amongst British and Irish gastroenterolo-
gists and hepatologists (A.H., unpublished data).
The Royal Liverpool Hospital is a tertiary-referral centre
for liver diseases. In September 2009, the Radiology
Department implemented a 6-monthly recall protocol for
US surveillance of all cirrhotic patients who were referred
by the hepatology and infectious diseases teams for HCC
surveillance. It had been observed that US booked as part of
clinic attendances were haphazard and results had the risk
of being overlooked. In addition, the US examinations were
frequently not performed in the recommended 6-monthly
time frame.
The present study originated as an internal service
evaluation of performance of the recall surveillance pro-
gramme. The primary aimwas to evaluate the detection rate
of HCC in surveillance. Secondary objectives were to
determine type and number of follow-up imaging in-
vestigations required, stage of disease at the time ofobe of the liver. (b) Arterial-phase CT. The liver lesion identiﬁed at US
es of the lesion, diagnostic of HCC.
e for hepatocellular carcinoma: service evaluation of a radiology-led
ical Radiology (2016), http://dx.doi.org/10.1016/j.crad.2016.10.019
Figure 2 (a) Surveillance US shows a large nodule in the right lobe of the liver. (b) Axial T2-weighted MRI. The lesion is T2 bright and het-
erogeneous. (c) Arterial phase MRI shows avid peripheral enhancement with central necrotic areas of hypo-enhancement. (d) Portal venous
phase MRI shows contrast washout with a peripheral enhancing pseudo-capsule. A radiological diagnosis of HCC was made.
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curative intent and assessment of adherence to surveillance.Materials and methods
A single-centre, retrospective study of patients who un-
derwent US HCC surveillance at The Royal Liverpool Hos-
pital between September 2009 and May 2013 was
performed. As the study was a service evaluation of rec-
ommended practice, ethics committee approval was not
required. The hospital’s radiology information system (RIS)
was searched using relevant key terms to identify all sur-
veillance scans between 1 September 2009 and 30 May
2013 (Electronic Supplementary Material Appendix S1).
This search strategy was necessary as there was no formal
US surveillance patient database. Liver US examinations for
patients not in surveillance were excluded from further
study.
Patients with a diagnosis of ChildePugh class A or B
cirrhosis of any aetiology were eligible for surveillance.
Non-cirrhotic patients with hepatitis B and a family history
of HCC were also offered surveillance. Patients with a prior
history of HCC or liver transplantation together with pa-
tients with ChildePugh class C cirrhosis (whowere not liver
transplant candidates) or with signiﬁcant co-morbidities
were to be excluded. A targeted US of the liver was per-
formed by a general radiologist or sonographer. If the ex-
amination did not identify lesions suspicious for HCC, the
patients were rebooked by the reporting radiologist or so-
nographer for a follow-up scan in 6 months. The date of thePlease cite this article in press as: Farrell C, et al., Ultrasound surveillanc
recall system in a tertiary-referral centre for liver diseases in the UK, Clinﬁrst surveillance US served as the index date. The number of
subsequent scans and their interval dates were recorded.
Complete follow-up was deﬁned as the patient receiving 6
monthly scans until either the end of the study, when HCC
was detected on surveillance and conﬁrmed, or if cessation
of surveillance was requested by the referring clinical team.
Reasons for cessation of HCC surveillance were not recor-
ded. Data collection included: patient demographics,
cirrhosis aetiology, total time period on surveillance, actual
number of scans performed, and projected number of scans
for each patient if surveillance had been completed. In
addition, the numbers of lesions suspicious for HCC
requiring further investigation and the modality used in
further investigations was recorded. For conﬁrmed HCCs,
the following data were collected from a hepatology
departmental database: number of tumour nodules, size of
the largest nodule, Barcelona Clinic Liver Cancer (BCLC)
stage, and treatment provided. All HCCs were identiﬁed:
both those found on routine surveillance scans and those
found on scans performed for other indications. Where HCC
was found on a scan performed for an indication other than
surveillance, the indication for the scan was recorded.
Duration of survival for the HCC cases was recorded; sur-
vival data were available until 28/6/16. The overall survival
and outcomes for the patients who did not have HCC was
not documented. Patients with inconsistent surveillance,
deﬁned as receiving at least one scan, but without appro-
priate follow-up scans, were considered “lost to follow-up”
if no reason for the incomplete surveillance could be iden-
tiﬁed. Patients whose scans were delayed by 6e12 weeks
were deemed to have suffered “minor delays.”e for hepatocellular carcinoma: service evaluation of a radiology-led
ical Radiology (2016), http://dx.doi.org/10.1016/j.crad.2016.10.019
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Continuous variables were presented as medians with
interquartile ranges. Frequencies were expressed as whole
numbers and percentages. Categorical variables were
compared using Fisher’s exact test where appropriate. He-
patocellular cancers detected were expressed as number of
cases per 100 patients per year.Results
Of the 6,725 patients identiﬁed via the RIS search criteria,
804 were conﬁrmed to be in the HCC surveillance pro-
gramme and were included in the analysis. The median age
of the entire cohort was 55 years (IQR 46e63) and 307 (38%)
were female. The aetiologies of the liver diseases are sum-
marized in Table 1. A total of 2,366 US surveillance scans
were performed. Abnormalities suspicious for HCC,
requiring further radiological investigation, were detected
in 81 patients (10% of patients, 3.4% of US examinations).
Twenty-three of these were characterised using computed
tomography (CT), 42 with magnetic resonance imaging
(MRI), 14 had both MRI and CT, and two had contrast-
enhanced US (CEUS) to characterise the lesion. Fourteen
of these 81 (17%) were conﬁrmed as having HCC, either on
imaging criteria or at biopsy. The US surveillance detection
rate of HCC for thewhole group was 1.2 per 100 patients per
year or 1.2%. A further eight patients were diagnosed with
HCC during the study period following an US examination
that was performed for an indication other than surveil-
lance. In total, 22 HCC cases were found in the surveillance
population, 14 (63%) on surveillance scans and eight (36%)
on scans other than surveillance US. Results are summar-
ised in Fig 3.
Conﬁrmed HCC cases
Twenty-two cases of HCC were identiﬁed. The median
age of patients with HCCwas 65 years (IQR 51e71), of which
seven (31%) were women. The aetiology of liver disease was
similar to that found in the overall surveillance population,
with ALD being the most frequent cause (Table 1). Hae-
mochromatosis showed a strong trend towards higher
prevalence in the HCC group, compared to the non-HCCTable 1
Aetiology of liver disease in surveillance population and hepatocellular car-
cinoma group.
Aetiology of liver disease n (%) n (%)
Alcoholic liver disease 308 (38%) 12 (39%)
HCV 154 (19%) 8 (26%)
HBV 113 (14%) 2 (6%)
Non-alcoholic hepatic steatosis 78 (10%) 5 (16%)
Primary biliary cirrhosis 37 (5%) 1 (3%)
Mixed aetiology 38 (5%) e
Haemochromatosis 22 (3%) 3 (10%)
Others 54 (7%) e
HCV, hepatitis C virus; HBV, hepatitis B virus.
Please cite this article in press as: Farrell C, et al., Ultrasound surveillanc
recall system in a tertiary-referral centre for liver diseases in the UK, Clingroup (3/22 HCC cases versus 19/782 non-HCC cases,
p¼0.02, Fisher’s exact test); however, numbers were small.
A summary of lesion characteristics is presented in Table 2.
There was no signiﬁcant difference in the size or number of
lesions in those HCC cases found via surveillance US
compared with those cases found at US performed for other
reasons. Therewas also no difference in the stage of disease;
however, the numbers of HCC cases were small, precluding
detailed analysis.
The patients in whom HCC was diagnosed on surveil-
lance US all attended for and received complete surveil-
lance. Of the eight patients who had HCC diagnosed on US
performed for a reason other than surveillance, six out of
eight (75%) received complete surveillance. The two pa-
tients who had not received complete surveillance had both
failed to attend for appointments.
Where HCC was diagnosed on US requested for in-
dications other than surveillance, in four cases the exami-
nation was performed for the investigation of raised AFP, in
two cases for abdominal symptoms, and in two cases for
vascular mapping pre-transjugular intrahepatic portosys-
temic shunt (TIPSS) placement.
Survival
Of 22 HCC patients, 16 (73%) had died as of 28 June 2016.
All patients who had HCC found at US performed for in-
dications other than surveillance had died, median survival
192 days (IQR 132e324). Of the patients with HCC found on
surveillance, six (43%) were still alive as of 28 June 2016,
median time from diagnosis 1,201 days (IQR 1,091e1,754).
The remainder of this group had a median survival of 782
days.
Treatment
On radiological criteria alone, 15/22 (68%) of the HCC
cases were eligible for curative treatment (BCLC 0-A), a
summary of stage and treatment intent are presented in
Table 2. Of the 14 patients whose HCC was identiﬁed on a
surveillance scan, 13 (93%) were treated with curative
intent. Eleven were treated with radiofrequency ablation
(RFA), one with RFA and irreversible electroporation, one
with RFA, and transarterial chemoembolisation (TACE) as a
bridge to transplant. This patient was listed for transplant
but was later delisted following disease progression. No
patients had local tumour resection. One patient was
treated palliatively with TACE.
Of the eight patients whose HCC was identiﬁed on a scan
other than a surveillance scan, two (25%) were treated with
curative intent. One underwent TACE as a bridge to trans-
plant and was placed on the transplant list, but was later
delisted following disease progression. One patient was
scheduled for RFA, but was found to have progression and
the ablation was not performed.
Of the six patients not treated with curative intent, four
were not offered any speciﬁc treatment, one was treated
with TACE and one was treated with systemic chemo-
therapy. Patients with HCC found on a surveillance scane for hepatocellular carcinoma: service evaluation of a radiology-led
ical Radiology (2016), http://dx.doi.org/10.1016/j.crad.2016.10.019
Figure 3 Summary of surveillance patients: reasons for failure to complete surveillance, numbers of abnormalities found, HCCs, and treatment
intention.
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those patients who had HCC found on a scan performed for
another indication (p¼0.002, Fisher’s exact test).
Uptake and adherence
The median number of surveillance US examinations per
patient was three (range 1e8) and the mean length of time
spent in surveillance was 17.4 months (range 6e42
months). New patients were continuously enrolled into the
programme over the study period. The total number of
surveillance scans performed was 2,366. Had all patients
received complete surveillance, the number of scans per-
formed would have been 3,495. Of all patients referred for
surveillance, 368 (46%) completed their expected follow-up
over the study period; 172 (21%) patients did not attend at
least one appointment (7% of scans). Radiologists/sonogra-
phers failed to rebook the next scan in 107 (13%) patients,
(this represents 5% of scans). In 78 (10%) patients, it was not
possible to identify the reason why surveillance was
incomplete. Forty (5%) patients suffered minor delays.
Thirty-nine (5%) were removed from surveillance either
temporarily or permanently for clinical reasons (e.g., other
co-morbidities, too ill to attend). Eighty-one patients (10%)
died during the surveillance period, or 6.85 per 100 patients
per year. It was not possible to ascertain cause of death by
searching the RIS.Please cite this article in press as: Farrell C, et al., Ultrasound surveillanc
recall system in a tertiary-referral centre for liver diseases in the UK, ClinDiscussion
The present study evaluated the feasibility and perfor-
mance of an informal, radiology led, 6-monthly US sur-
veillance programme for the detection of HCC. Evidence for
surveillance is limited, but a 2014 meta-analysis on early
detection, curative treatment, and survival rates for HCC
surveillance by Singal et al.14 reported signiﬁcant beneﬁts,
with increases in early detection and curative treatment
rates, (odds ratio 2.24). A survival beneﬁt was found in
surveillance compared with non-surveillance patients
(odds ratio 1.9), which persisted in those studies adjusting
for lead time bias. The paper acknowledged that none of the
studies included in their analysis assessed harm or cost-
effectiveness. Current guidelines on surveillance and ex-
pectations of patients and clinicians mean that informal
surveillance programmes are increasingly being imple-
mented, while randomised, controlled trials (RCTs) are no
longer considered ethical.9e11,15 An impasse has, therefore,
arisen in which funding for surveillance is withheld due to
lack of evidence, yet the investigations can no longer be
refused on clinical grounds.
In the present study, 81 abnormal US examinations were
identiﬁed out of 2,366, of which 83% were false positives,
while17%ofpatientswith adetectedabnormalityonUSwere
subsequently diagnosed with HCC. Positive survivale for hepatocellular carcinoma: service evaluation of a radiology-led
ical Radiology (2016), http://dx.doi.org/10.1016/j.crad.2016.10.019
Table 2
Lesion number, size, staging, treatment intent, and survival in hepatocellular
carcinoma (HCC) cases.
All cases HCC found
on surveillance
ultrasound
HCC not found
on surveillance
ultrasound
22 14 8
Number of lesions
1 13 (59) 6 (43) 7 (88)
2 3 (14) 3 (21) 0 (0)
3 2 (9) 2 (14) 0 (0)
4 4 (18) 3 (21) 1 (12)
Size of largest lesion, cm
2 10 (45) 6 (43) 4 (50)
2.1e5 12 (55) 8 (57) 4 (50)
Barcelona Clinic Liver Cancer (BCLC) stage
0 5 (23) 3 (21) 2 (25)
A 10 (45) 7 (50) 3 (38)
B 4 (18) 2 (14) 2 (25)
C 1 (5) 1 (7) 0 (0)
D 2 (9) 1 (7) 1 (12)
Within Milan Transplant Criteria
Yes 17 (77) 11 (79) 6 (75)
No 5 (23) 3 (21) 2 (25)
Treatment with curative intent
Yes 15 (68) 13 (93) 2 (25)
No 7 (32) 1 (7) 6 (75)
Alive as of June 2016 6 (27) 6 (43) 0 (0)
Median survival post
diagnosis for deceased
patients (days)
387 782 192
C. Farrell et al. / Clinical Radiology xxx (2016) e1ee7e6outcomeswere achieved in this groupwith six patients (43%)
alive between 2.8 and 5.4 years after diagnosis, and amedian
survival for the remainder of these patients of 782 days.
In contrast, eight patients in the surveillance cohort
presentedwith HCC found as a result of investigations other
than surveillance US. Six (75%) of these patients had
received complete surveillance and can, therefore, be clas-
siﬁed as interval cancers, a marker used as an important
statistical benchmark to assess the efﬁcacy of other
screening programmes, particularly mammographic
screening.16 There are several possible explanations for in-
terval presentation: the lesions were truly new, were mis-
interpreted as benign, or were missed (false-negative
examinations). Although numbers are small, it is worth
noting that a single lesion was present more frequently in
this group. This may have increased the likelihood of a false-
negative scan. Interestingly, although the HCC stage at
presentation in these patients was not signiﬁcantly
different from the HCC cases found on surveillance, only
two of these patients were treated with curative intent and
all had died by 28 June 2016 with a median survival of 192
days. Two were undergoing investigation of abdominal
symptoms, and two were awaiting TIPSS. In contrast, the
HCC cases found at surveillance were likely asymptomatic.
Although numbers are small, the present ﬁndings are in
keeping with the published literature suggesting a survival
beneﬁt for surveillance.
The false-negative rate in this population is unknown, as
follow-up of patients with negative scan results was not
conducted. A signiﬁcant number of patients dropped out
(12%) or died (10%) during surveillance for which a causePlease cite this article in press as: Farrell C, et al., Ultrasound surveillanc
recall system in a tertiary-referral centre for liver diseases in the UK, Clincould not be identiﬁed and some of these could be attrib-
uted to HCC. In addition, the present detection rates were
not compared with rates of HCC in patients who had never
been in surveillance.
Although the overall adherence to surveillance was only
46% in this informal recall programme, interestingly, the
attendance rate was signiﬁcantly higher in the group with
HCC (91%) andmore in linewith other, established, andwell-
funded screening programmes. Attendance currently stands
at 72% for breast cancer,17 70% for cervical cancer,18 and
55e60% for bowel cancer.19 A total of 2,447 US examinations
wouldhavebeenperformedatapresumedattendance rateof
70%. Failings in the recall protocol were exposed with 112
patients not being recalled for examination. This was mainly
due to operators not adding the rebook code to the scan
report; a failure that might not have occurred in a formal
screening setting with better recall mechanisms in place. At
8%, the rateofnon-attendance for rebookedscanswas similar
to that for other appointments in the department. The failure
of patients to attend is likely multifactorial. As well as com-
mon causes, such as forgetting an appointment, illness, or
change of address, a misunderstanding as to why the USwas
being performed may have contributed, in particular as pa-
tientsunder surveillance are generallyasymptomatic. Should
surveillance continue to be recommended, these factors will
also need to be clariﬁed in further studies and appropriate
information material developed to support adherence.
Although there is no robust evidence on the beneﬁts versus
harmof surveillance, noroncost-effectiveness, it is likely that
current practice will continue and expand, at least until any
information to the contrary should become available. Indeed,
in the UK, the present government has set targets to reduce
cancer deaths by earlier disease detection and HCC surveil-
lancemay be promoted as one of themeans of achieving this.
In 2014, the Royal College of Radiologists issued a position
statementon theuseofUS surveillance forHCC.13 It alludes to
the absence of strong data indicating a decrease in disease-
speciﬁc mortality and the lack of ﬁnancial and administra-
tive support seen in other screening programmes. The pre-
sent ﬁndings illustrate that an informal system, run by
goodwill from the radiology department without appro-
priate support and funding is suboptimal andmay leave early
cancers undetected in patients who do not receive complete
surveillance. A large number of US examinations was
required to detect a small number of potentially curable
cases, but an even larger number of scans would have been
required to reach acceptable standards of screening atten-
dance. The resource implications are signiﬁcant, and it is
unlikely that high-quality surveillance will be adopted
widely without appropriate funding.
The limited accuracy of US for the detection of liver le-
sions, in particular in cirrhotic and obese patients, is
another area of concern as it invariably leads to further
imaging in suspected cases, although in this study the
number of referrals for further imaging was relatively small
(10%). As it may potentially become higher, once data on
false-negative rates become available and more vigorous
additional imaging may be recommended, this will also
need to be taken into account in the funding of surveillance.e for hepatocellular carcinoma: service evaluation of a radiology-led
ical Radiology (2016), http://dx.doi.org/10.1016/j.crad.2016.10.019
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are required such as biomarkers and/or composite scores to
gauge the risk of HCC in a particular individual. At present,
US is the best modality available and informal surveillance
is the best available option for at risk patients.
To resolve the above-mentioned impasse, in the absence
of a fully funded surveillance programme, at the very least,
funding should be provided for high-quality studies of cur-
rent surveillance practice to obtain the evidence that can no
longer be acquired through RCTs. With limited access to
funding, the evaluation of current service provision suffered
from a number of limitations: most datawere obtained from
the RIS and only clinical notes of patients with a conﬁrmed
HCC could be reviewed. Subsequently, no follow-up data are
available onpatientswith negative scan results. The accuracy
of US in this population could not be assessed, nor exactly
why a signiﬁcant number of patients dropped out of sur-
veillance orwhyoperators did not arrange the agreed recalls.
In conclusion, the present study supports previous
ﬁndings that surveillance can lead to improved survival
rates for HCC; however, it also highlights the challenges of
performing US surveillance for HCC in the absence of
appropriate funding and administrative frameworks. The
ﬁnding that adherence to surveillance and patient inclusion
were suboptimal, even in an environment dedicated to
successful surveillance, supports the argument that high-
quality surveillance is unlikely without appropriate in-
vestment. Despite the limitations, this study provides an
indication of expected HCC detection rates in a UK popu-
lation, the frequency of further investigations required, and
the number of HCC cases actually proceeding to treatment
with curative intent. This information, given the paucity of
UK data in this area, could act as a benchmark against which
much needed future studies are designed and compared.
Appendix A. Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.crad.2016.10.019.
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